Ali Ardakani is a technical and entrepreneurial corporate development and operations biotech executive with 20 years of experience in managing life science projects and companies. His experience includes managing R&D projects in the areas of oncology, respiratory, infectious disease, CNS therapeutics and medical devices, as well as fundraising, licensing and M&A.
Ali is the Founder & Managing Director of Novateur Ventures. Until recently he was Senior Vice President Device & Business Development for Beyond Air (NASDAQ:XAIR), where he was involved with the company from early stage until Nasdaq public offering and several rounds of financing and licensing. He is the CEO and co-founder of Optigo Biotherapeutics, an ophthalmology R&D company, the Vice Chair of LifeSciences BC, and Entrepreneur in Residence at Innovate Calgary. He is also an Associate at Creative Destruction Labs. He was the Co-Founder and COO of Niiki Pharma, which was acquired in 2013 by Intezyne Technologies, of which he became the Vice President.
To date, Ali has taken several projects from concept to FDA approval, with two 510(k) approvals for medical devices and two FDA IND approvals. He has also worked on commercialization and pharma partnerships, as well as several global mergers and acquisitions.